215 related articles for article (PubMed ID: 31605171)
1. Prognostic Assessment of Non-functioning Neuroendocrine Pancreatic Neoplasms as a Basis for Risk-Adapted Resection Strategies.
Watzka FM; Meyer F; Staubitz JI; Fottner C; Schad A; Lang H; Musholt TJ
World J Surg; 2020 Feb; 44(2):594-603. PubMed ID: 31605171
[TBL] [Abstract][Full Text] [Related]
2. Outcome of surgery for pancreatic neuroendocrine neoplasms.
Fischer L; Bergmann F; Schimmack S; Hinz U; Prieß S; Müller-Stich BP; Werner J; Hackert T; Büchler MW
Br J Surg; 2014 Oct; 101(11):1405-12. PubMed ID: 25132004
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors after resection of locally advanced non-functional pancreatic neuroendocrine neoplasm: an analysis from the German Cancer Registry Group of the Society of German Tumor Centers.
Abdalla TSA; Klinkhammer-Schalke M; Zeissig SR; Tol KK; Honselmann KC; Braun R; Bolm L; Lapshyn H; Litkevych S; Zemskov S; Begum N; Kulemann B; Hummel R; Wellner UF; Keck T; Deichmann S
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8535-8543. PubMed ID: 37095413
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
5. Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately.
Yoshida T; Hijioka S; Hosoda W; Ueno M; Furukawa M; Kobayashi N; Ikeda M; Ito T; Kodama Y; Morizane C; Notohara K; Taguchi H; Kitano M; Yane K; Tsuchiya Y; Komoto I; Tanaka H; Tsuji A; Hashigo S; Mine T; Kanno A; Murohisa G; Miyabe K; Takagi T; Matayoshi N; Sakaguchi M; Ishii H; Kojima Y; Matsuo K; Yoshitomi H; Nakamori S; Yanagimoto H; Yatabe Y; Furuse J; Mizuno N
Ann Surg Oncol; 2019 May; 26(5):1385-1393. PubMed ID: 30863939
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification.
Deng BY; Liu F; Yin SN; Chen AP; Xu L; Li B
Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):261-268. PubMed ID: 29307515
[TBL] [Abstract][Full Text] [Related]
7. Exploring the surgical landscape of pancreatic neuroendocrine neoplasia in Austria: Results from the ASSO pNEN study group.
Primavesi F; Klieser E; Cardini B; Marsoner K; Fröschl U; Thalhammer S; Fischer I; Hauer A; Urbas R; Kiesslich T; Neureiter D; Zitt M; Klug R; Wundsam H; Sellner F; Karner J; Függer R; Cakar-Beck F; Kornprat P; Öfner D; Stättner S;
Eur J Surg Oncol; 2019 Feb; 45(2):198-206. PubMed ID: 30262324
[TBL] [Abstract][Full Text] [Related]
8. Resection of Non-Functional Pancreatic Neuroendocrine Neoplasms-A Single-Center Retrospective Outcome Analysis.
Lindner K; Binte D; Hoeppner J; Wellner UF; Schulte DM; Schmid SM; Luley K; Buchmann I; Tharun L; Keck T; Gebauer J; Kulemann B
Curr Oncol; 2021 Aug; 28(4):3071-3080. PubMed ID: 34436034
[TBL] [Abstract][Full Text] [Related]
9. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the World Health Organization 2010 grading system in surgical outcome and prognosis of pancreatic neuroendocrine tumors.
Yang M; Tian BL; Zhang Y; Su AP; Yue PJ; Xu S; Wang L
Pancreas; 2014 Oct; 43(7):1003-8. PubMed ID: 24945681
[TBL] [Abstract][Full Text] [Related]
11. Survival following resection of pancreatic endocrine tumors: importance of R-status and the WHO and TNM classification systems.
Pomianowska E; Gladhaug IP; Grzyb K; Røsok BI; Edwin B; Bergestuen DS; Mathisen O
Scand J Gastroenterol; 2010 Aug; 45(7-8):971-9. PubMed ID: 20441530
[TBL] [Abstract][Full Text] [Related]
12. Increased Grade in Neuroendocrine Tumor Metastases Negatively Impacts Survival.
Keck KJ; Choi A; Maxwell JE; Li G; O'Dorisio TM; Breheny P; Bellizzi AM; Howe JR
Ann Surg Oncol; 2017 Aug; 24(8):2206-2212. PubMed ID: 28560597
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study.
Tong Z; Liu L; Zheng Y; Jiang W; Zhao P; Fang W; Wang W
World J Surg Oncol; 2017 May; 15(1):108. PubMed ID: 28558772
[TBL] [Abstract][Full Text] [Related]
14. A wait-and-watch approach to small pancreatic neuroendocrine tumors: prognosis and survival.
Massironi S; Rossi RE; Zilli A; Casazza G; Ciafardini C; Conte D
Oncotarget; 2016 Apr; 7(14):18978-83. PubMed ID: 26959887
[TBL] [Abstract][Full Text] [Related]
15. [Clinicopathologic characteristics and prognosis of rectal neuroendocrine neoplasms].
Liu T; Liu P; Wu T; Pan Y; Chen G; Wang P; Jiang Y; Wu Y; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1015-1019. PubMed ID: 28900992
[TBL] [Abstract][Full Text] [Related]
16. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection.
Lv Y; Han X; Xu XF; Ji Y; Zhou YH; Sun HC; Zhou J; Fan J; Lou WH; Huang C
BMC Cancer; 2019 Apr; 19(1):335. PubMed ID: 30961559
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome of surgical resection in patients with gastroenteropancreatic neuroendocrine neoplasia: results from a German nation-wide multi-centric registry.
Begum N; Maasberg S; Pascher A; Plöckinger U; Gress TM; Wurst C; Weber F; Raffel A; Krausch M; Holzer K; Bartsch DK; Musholt TJ; Keck T; Anlauf M; Rinke A; Pape UF; Goretzki PE;
Langenbecks Arch Surg; 2020 Mar; 405(2):145-154. PubMed ID: 32372309
[TBL] [Abstract][Full Text] [Related]
18. Reconsideration of operative indications in pancreatic neuroendocrine neoplasms.
Abe K; Kitago M; Iwasaki E; Yagi H; Abe Y; Hasegawa Y; Hori S; Tanaka M; Nakano Y; Kitagawa Y
World J Surg Oncol; 2022 Nov; 20(1):366. PubMed ID: 36397094
[TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine tumors of the pancreas: a retrospective single-center analysis using the ENETS TNM-classification and immunohistochemical markers for risk stratification.
Brunner SM; Weber F; Werner JM; Agha A; Farkas SA; Schlitt HJ; Hornung M
BMC Surg; 2015 Apr; 15():49. PubMed ID: 25928025
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors and survival after surgical resection of pancreatic neuroendocrine tumor with validation of established and modified staging systems.
Benetatos N; Hodson J; Marudanayagam R; Sutcliffe RP; Isaac JR; Ayuk J; Shah T; Roberts KJ
Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):169-175. PubMed ID: 29576279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
